

Renato Bernardini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4676764/publications.pdf>

Version: 2024-02-01

89

papers

2,938

citations

201658

27

h-index

182417

51

g-index

96

all docs

96

docs citations

96

times ranked

3566

citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112558.	5.6	10
2	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112516.	5.6	38
3	Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease. <i>Neurotherapeutics</i> , 2022, 19, 305-324.	4.4	3
4	Ampicillin plus ceftriaxone therapy against <i>Enterococcus faecalis</i> endocarditis: A case report, guidelines considerations, and literature review. <i>IDCases</i> , 2022, 28, e01462.	0.9	4
5	Intranasal Administration of a TRAIL Neutralizing Monoclonal Antibody Adsorbed in PLGA Nanoparticles and NLC Nanosystems: An In Vivo Study on a Mouse Model of Alzheimer's Disease. <i>Biomedicines</i> , 2022, 10, 985.	3.2	13
6	Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations. <i>Infectious Disease Reports</i> , 2022, 14, 360-371.	3.1	14
7	COVID Vaccination in Cancer Patients: What Vaccination Priority Strategies Should There Be?. <i>Frontiers in Oncology</i> , 2021, 11, 641388.	2.8	10
8	Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1906.	3.7	6
9	Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence. <i>Current Pharmaceutical Design</i> , 2021, 27, 1323-1329.	1.9	0
10	In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 1013-1025.	5.7	6
11	Brimonidine is Neuroprotective in Animal Paradigm of Retinal Ganglion Cell Damage. <i>Frontiers in Pharmacology</i> , 2021, 12, 705405.	3.5	30
12	Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. <i>Biomedicines</i> , 2021, 9, 1075.	3.2	46
13	Stem Cells: Innovative Therapeutic Options for Neurodegenerative Diseases?. <i>Cells</i> , 2021, 10, 1992.	4.1	18
14	Beneficial Effects of Choline Alphoscerate on Amyloid- β Neurotoxicity in an In vitro Model of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2021, 18, 298-309.	1.4	2
15	The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10719.	4.1	36
16	Ampicillin Plus Ceftriaxone Regimen against <i>Enterococcus faecalis</i> Endocarditis: A Literature Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 4594.	2.4	25
17	Targeting the miRNA-155/TNFSF10 network restrains inflammatory response in the retina in a mouse model of Alzheimer's disease. <i>Cell Death and Disease</i> , 2021, 12, 905.	6.3	16
18	A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine. <i>Frontiers in Immunology</i> , 2021, 12, 788211.	4.8	5

#	ARTICLE	IF	CITATIONS
19	The immune system on the TRAIL of Alzheimer's disease. Journal of Neuroinflammation, 2020, 17, 298.	7.2	42
20	On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents. Frontiers in Oncology, 2020, 10, 1340.	2.8	3
21	Repositioning of Immunomodulators: A Ray of Hope for Alzheimer's Disease?. Frontiers in Neuroscience, 2020, 14, 614643.	2.8	16
22	We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database. Frontiers in Psychiatry, 2020, 11, 550201.	2.6	10
23	A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatments. Breast, 2020, 52, 78-87.	2.2	7
24	Beneficial effects of curtailing immune susceptibility in an Alzheimer's disease model. Journal of Neuroinflammation, 2019, 16, 166.	7.2	27
25	Ocular Pharmacological Profile of Hydrocortisone in Dry Eye Disease. Frontiers in Pharmacology, 2019, 10, 1240.	3.5	27
26	The Biochemical and Pharmacological Properties of Ozone: The Smell of Protection in Acute and Chronic Diseases. International Journal of Molecular Sciences, 2019, 20, 634.	4.1	70
27	Tumor necrosis factor-related apoptosis-inducing ligand reduces the expression of the neuroprotective Na ⁺ /Ca ²⁺ exchanger isoform NCX 3 in human neuroblastoma SH-SY 5Y cells. FEBS Journal, 2019, 286, 737-749.	4.7	4
28	Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 133-140.	1.3	14
29	Functional Changes of Orexinergic Reaction to Psychoactive Substances. Molecular Neurobiology, 2018, 55, 6362-6368.	4.0	29
30	The Role of Anabolic Androgenic Steroids in Disruption of the Physiological Function in Discrete Areas of the Central Nervous System. Molecular Neurobiology, 2018, 55, 5548-5556.	4.0	38
31	Inhibition of aldose-reductase-2 by a benzofuroxane derivative bf-5m increases the expression of kcnk1, kcnq1 in high glucose cultured H9c2 cardiac cells and sudden cardiac death. Oncotarget, 2018, 9, 17257-17269.	1.8	6
32	Redundant modulatory effects of proinflammatory cytokines in human osteoblastic cells in vitro. Clinical and Experimental Rheumatology, 2018, 36, 959-969.	0.8	2
33	The efficacy of an association of palmitoylethanolamide and alpha-lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial. Archivio Italiano Di Urologia Andrologia, 2017, 89, 17.	0.8	13
34	The Proinflammatory Cytokine GITRL Contributes to TRAIL-mediated Neurotoxicity in the HCN-2 Human Neuronal Cell Line. Current Alzheimer Research, 2017, 14, 1090-1101.	1.4	4
35	Remifentanyl and worse patient-reported outcomes regarding postoperative pain management after thyroidectomy. Journal of Clinical Anesthesia, 2016, 31, 27-33.	1.6	19
36	Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. Expert Opinion on Drug Safety, 2016, 15, 1-8.	2.4	20

#	ARTICLE	IF	CITATIONS
37	Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 285-293.	1.9	21
38	Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1601-e1609.	2.2	14
39	Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease. <i>Brain</i> , 2015, 138, 203-216.	7.6	62
40	Involvement of caspase-8 and -9 and FLIP in the proangiogenic effects of the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). <i>FEBS Journal</i> , 2014, 281, 1505-1513.	4.7	13
41	CHF5074 Protects SH-SY5Y Human Neuronal-like Cells from Amyloid-beta 25-35 and Tumor Necrosis Factor Related Apoptosis Inducing Ligand Toxicity In Vitro. <i>Current Alzheimer Research</i> , 2014, 11, 714-724.	1.4	16
42	Nerve growth factor (NGF) levels in follicular fluid of infertile patients undergoing to in vitro fertilization (IVF) cycle. <i>Gynecological Endocrinology</i> , 2013, 29, 1002-1004.	1.7	9
43	Glutamate-Induced ATP Synthesis: Relationship between Plasma Membrane Na ⁺ /Ca ²⁺ Exchanger and Excitatory Amino Acid Transporters in Brain and Heart Cell Models. <i>Molecular Pharmacology</i> , 2013, 84, 603-614.	2.3	44
44	The antimitogenic effect of the cannabinoid receptor agonist WIN55212-2 on human melanoma cells is mediated by the membrane lipid raft. <i>Cancer Letters</i> , 2011, 310, 240-249.	7.2	21
45	Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. <i>Biochemical Pharmacology</i> , 2011, 82, 380-388.	4.4	74
46	Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 433-438.	5.5	34
47	Neutralization of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Reduces Spinal Cord Injury Damage in Mice. <i>Neuropsychopharmacology</i> , 2010, 35, 1302-1314.	5.4	30
48	Sorafenib: Rays of Hope in Thyroid Cancer. <i>Thyroid</i> , 2010, 20, 1351-1358.	4.5	19
49	The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro. <i>European Journal of Pharmacology</i> , 2009, 616, 16-21.	3.5	27
50	Amylin prevents TRAIL-mediated apoptotic effects of reserpine in the rat gastric mucosa. <i>Peptides</i> , 2009, 30, 1466-1472.	2.4	6
51	Symptomatic hypocalcemia in an epileptic child treated with valproic acid plus lamotrigine: a case report. <i>Cases Journal</i> , 2009, 2, 7394.	0.4	9
52	TRAIL-related neurotoxicity implies interaction with the Wnt pathway in human neuronal cells in vitro. <i>Journal of Neurochemistry</i> , 2008, 105, 1915-1923.	3.9	15
53	Recombinant human TNF-binding protein-1 (rhTBP-1) treatment delays both symptoms progression and motor neuron loss in the wobbler mouse. <i>Neurobiology of Disease</i> , 2008, 29, 465-476.	4.4	23
54	The role of antioxidant supplement in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk/benefit profile. <i>Nutrition Journal</i> , 2008, 7, 29.	3.4	104

#	ARTICLE	IF	CITATIONS
55	Protective effects of the sigma agonist Pre-084 in the rat retina. British Journal of Ophthalmology, 2007, 91, 1382-1384.	3.9	29
56	Protective effects of amylin on reserpine-induced gastric damage in the rat. Pharmacological Research, 2007, 56, 27-34.	7.1	19
57	Trail interacts redundantly with nitric oxide in rat astrocytes: Potential contribution to neurodegenerative processes. Journal of Neuroimmunology, 2007, 182, 41-47.	2.3	23
58	Levels of matrix metalloproteinases 1 and 2 in human gingival crevicular fluid during initial tooth movement. American Journal of Orthodontics and Dentofacial Orthopedics, 2006, 130, 568.e11-568.e16.	1.7	43
59	Adrenomedullin modulates COX-2 and HGF expression in reserpine-injured gastric mucosa in the rat. European Journal of Pharmacology, 2005, 518, 221-226.	3.5	18
60	Effect of adrenomedullin on c-Met receptor expression after reserpine-induced gastric damage in the rat. European Journal of Pharmacology, 2004, 488, 219-224.	3.5	3
61	Role of Magnesium, Coenzyme Q10, Riboflavin, and Vitamin B12 in Migraine Prophylaxis. Vitamins and Hormones, 2004, 69, 297-312.	1.7	58
62	TRAIL is expressed in the brain cells of Alzheimer's disease patients. NeuroReport, 2004, 15, 579-581.	1.2	45
63	Synthesis of new P3CS derivatives and their mitogenic activity on in vitro mice splenocytes. Il Farmaco, 2003, 58, 329-336.	0.9	2
64	Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycemia and insulinitis by a recombinant IL-18-binding protein: Fc construct. European Journal of Immunology, 2003, 33, 2278-2286.	2.9	37
65	Growth hormone protects human lymphocytes from irradiation-induced cell death. British Journal of Pharmacology, 2003, 138, 1411-1416.	5.4	28
66	Psychoneuroendocrinological links between chronic stress and depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 893-903.	4.8	178
67	Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB Journal, 2002, 16, 1307-1309.	0.5	214
68	Increased ACTH and cortisol secretion after interleukin-1 β injection in the common marmoset (Callithrix jacchus jacchus). Life Sciences, 2001, 68, 1657-1665.	4.3	3
69	Divergent effects of corticotropin releasing hormone on endothelial cell nitric oxide synthase are associated with different expression of CRH type 1 and 2 receptors. British Journal of Pharmacology, 2001, 134, 837-844.	5.4	30
70	Apomorphine, dopamine and phenylethylamine reduce the proportion of phosphorylated insulin receptor substrate 1. European Journal of Pharmacology, 2001, 433, 47-54.	3.5	11
71	Responsiveness of Irradiated Rat Anterior Pituitary Cells to Hypothalamic Releasing Hormones Is Restored by Treatment with Growth Hormone. Neuroendocrinology, 2000, 72, 392-399.	2.5	8
72	Synthesis and Immunostimulating Activity of A Thioglycolipopeptide Glycomimetic As A Potential Anticancer Vaccine Derived From Tn Antigen. Journal of Carbohydrate Chemistry, 2000, 19, 527-541.	1.1	44

#	ARTICLE	IF	CITATIONS
73	Mitogenic Effect of Nerve Growth Factor (NGF) in LNCaP Prostate Adenocarcinoma Cells: Role of the High- and Low-Affinity NGF Receptors. <i>Molecular Endocrinology</i> , 2000, 14, 124-136.	3.7	44
74	Mitogenic Effect of Nerve Growth Factor (NGF) in LNCaP Prostate Adenocarcinoma Cells: Role of the High- and Low-Affinity NGF Receptors. <i>Molecular Endocrinology</i> , 2000, 14, 124-136.	3.7	6
75	Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells. <i>Neurotoxicity Research</i> , 1999, 1, 285-297.	2.7	7
76	Adenylate-Cyclase-Dependent Pituitary Adrenocorticotropin Secretion Is Defective in the Inflammatory-Disease-Susceptible Lewis Rat. <i>Neuroendocrinology</i> , 1996, 63, 468-474.	2.5	9
77	Is Side-Stream Smoke a Stressor?. <i>Indoor and Built Environment</i> , 1995, 4, 157-161.	2.8	0
78	In vivo and in vitro Effects of Arginine-Vasopressin Receptor Antagonists on the Hypothalamic-Pituitary-Adrenal Axis in the Rat. <i>Neuroendocrinology</i> , 1994, 60, 503-508.	2.5	25
79	Neurotransmitter-Induced Hypothalamic-Pituitary-Adrenal Axis Responsiveness Is Defective in Inflammatory Disease-Susceptible Lewis Rats: In vivo and in vitro Studies Suggesting Globally Defective Hypothalamic Secretion of Corticotropin-Releasing Hormone. <i>Neuroendocrinology</i> , 1992, 55, 600-608.	2.5	114
80	Plasma β -endorphin levels and natural killer cells in two cases of congenital indifference to pain. <i>Child's Nervous System</i> , 1992, 8, 83-85.	1.1	4
81	Chronic Sodium or Chloride Depletion Upregulates Angiotensin II Receptors in the Anterior Pituitary Lobe of Young Rats. <i>Neuroendocrinology</i> , 1991, 53, 556-561.	2.5	3
82	Interactions between Tumor Necrosis Factor- α , Hypothalamic Corticotropin-Releasing Hormone, and Adrenocorticotropin Secretion in the Rat*. <i>Endocrinology</i> , 1990, 126, 2876-2881.	2.8	222
83	Mediators of the inflammatory/immune response: Relevance to the hypothalamic-pituitary-adrenal axis. <i>Pharmacological Research</i> , 1990, 22, 46.	7.1	1
84	Rat hypothalamic corticotropin-releasing hormone secretion is stimulated by interleukin-1 in an eicosanoid-dependent manner. <i>Life Sciences</i> , 1990, 47, 1601-1607.	4.3	61
85	The Alkyl-Ether Phospholipid Platelet-Activating Factor is a Stimulator of the Hypothalamic-Pituitary-Adrenal Axis in the Rat*. <i>Endocrinology</i> , 1989, 125, 1067-1073.	2.8	44
86	Effects of serotonergic agonists and antagonists on corticotropin-releasing hormone secretion by explanted rat hypothalami. <i>Peptides</i> , 1989, 10, 189-200.	2.4	221
87	Arachidonic Acid Metabolites Modulate Rat Hypothalamic Corticotropin-Releasing Hormone Secretion in vitro. <i>Neuroendocrinology</i> , 1989, 50, 708-715.	2.5	81
88	Effect of Cholinergic Agonists and Antagonists on Rat Hypothalamic Corticotropin-Releasing Hormone Secretion in vitro. <i>Neuroendocrinology</i> , 1988, 47, 303-308.	2.5	92
89	Regulation of Rat Hypothalamic Corticotropin-Releasing Hormone Secretion in vitro: Potential Clinical Implications. <i>Advances in Experimental Medicine and Biology</i> , 1988, 245, 167-181.	1.6	37